| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
ODN-2007 (ODN2007) is a novel class B CpG ODN (oligodeoxynucleotide) acitng as a Toll-like receptor (TLR) agonit/ligand, and can be used as an immunomodulator and vaccine adjuvant to enhance immune responses in mammals, fish, and humans. Sequence: 5'-TCGTCGTTGTCGTTTTGTCGTT-3'.
| ln Vitro |
ODN 2007 (1 or 5 μg/mL, 3–18 h) strongly increases the expression of interferon IFN-γ and IFN-β in chicken macrophages[1]. ODN 2007 (10 μg/mL, 0.5–12 h) can raise AKT and ERK2 phosphorylation levels and promote NO production[3].
|
|---|---|
| ln Vivo |
Through controlling the expression of genes linked to the immune system in zebrafish infected with Vibrio traumaticus FJ03-X2, ODN 2007 (intraperitoneal injection, 1 μg, once) can improve the immunological response[2].
|
| Cell Assay |
RT-PCR[1]
Cell Types: MQ-NCSU cells (a chicken macrophage cell line) Tested Concentrations: 1 μg/mL, 5 μg/mL Incubation Duration: 3 h, 12 h, 18 h Experimental Results: Dramatically stimulated an increase in transcriptional expression of IFN-γ after 3 hrs (hours) regardless of the dose. Increased the mRNA expression of IL-1β at 5 μg/mL high dose regardless of the time point. Western Blot Analysis[3] Cell Types: HD11, a replication-deficient avian leukemia virus MC29-transformed macrophage-like cell line Tested Concentrations: 10 μg/mL Incubation Duration: 0.5 h, 1 h, 3 h, 6 h, 12 h Experimental Results: Resulted in a significant increase in ERK2 and AKT phosphorylation levels and increased IFN-γ, IL-6 and MIP-3α mRNA levels. Stimulated an increase in the level of NO. |
| Animal Protocol |
Animal/Disease Models: Zebrafish infected with Vibrio traumaticus FJ03-X2[2]
Doses: 1 μg Route of Administration: intraperitoneal (ip)injection; once Experimental Results: demonstrated a cumulative mortality rate of 15.0% in treated group while the control group reached 42.1%. demonstrated a significant decrease in the expression levels of all intestinal immune-related genes such as TNF, IFNg1-2, IL-1β, IL-10, especially IL-1β diminished by 99.88%. |
| References |
|
| Molecular Formula |
NA??MOLECULARWEIGHT
|
|---|---|
| Molecular Weight |
0
|
| CAS # |
455348-63-7
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~20 mg/mL (~2.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
